World

AstraZeneca thinks shot can stop severe disease from South Africa COVID variant


AstraZeneca confirmed that early data from a small trial, first reported by the Financial Times, had shown limited efficacy for the vaccine against mild disease primarily due to this variant.

British drugmaker AstraZeneca said on Saturday it believed its COVID-19 vaccine, developed with the University of Oxford, could protect against severe disease caused by the South African variant of the virus.

AstraZeneca confirmed that early data from a small trial, first reported by the Financial Times, had shown limited efficacy for the vaccine against mild disease primarily due to this variant.

“We do believe our vaccine could protect against severe disease, as neutralising antibody activity is equivalent to that of other COVID-19 vaccines that have demonstrated activity against more severe disease, particularly when the dosing interval is optimised to 8-12 weeks,” a spokesman said in a statement.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.



Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button